News Aktuell

RHEACELL GmbH und Co. KG

24.09.2024 - 12:25

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

Heidelberg, Germany (ots) - - FDA approved blinded, multi-centric Phase-3 trial (NCT06489028) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU - The study will be conducted at more than 100 sites and is expected to enroll ...To the press release of RHEACELL GmbH und Co. KG

One image:
Preview HiResDownload

28.02.2024 - 15:00

Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘

Heidelberg (ots) - On February 29, 2024, Rare Disease Day will take place worldwide to raise awareness for rare diseases. Only 5% of the approximately 6,000 to 10,000 known rare diseases are currently treatable. The research and development of ...To the press release of RHEACELL GmbH und Co. KG

One image:
Preview HiResDownload

27.06.2023 - 11:23

RHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected

Heidelberg (ots) - Stem cell therapy for "butterfly disease" Following positive phase IIa study results, the biopharmaceutical company RHEACELL starts a multi-centre, global phase III study for the clinical testing of its stem cell therapeutic based ...To the press release of RHEACELL GmbH und Co. KG

One image:
Preview HiResDownload

09.11.2022 - 10:39

Stem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research

Heidelberg (ots) - The biopharmaceutical company RHEACELL, which specializes in stem cells, was honored on October 24 by the organization 'Dystrophic Epidermolysis Bullosa Research Association of America' (debra) with the ‘Partners in Progress ...To the press release of RHEACELL GmbH und Co. KG

One image:
Preview HiResDownload